The  	The  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
integrase  	integrase  	 JJ	B-NP
inhibitors  	inhibitors  	 NN	I-NP
in  	in  	 IN	O
treatment-experienced  	treatment-experienced  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
Raltegravir 	Raltegravir 	 NNP	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
first  	first  	 JJ	O
approved  	approved  	 FW	B-NP
HIV-1  	HIV-1  	 FW	I-NP
integrase  	integrase  	 FW	I-NP
inhibitor 	inhibitor 	 FW	I-NP
,  	,  	 ,	O
is  	is  	 VBZ	O
able  	able  	 JJ	O
to  	to  	 TO	O
block  	block  	 VB	O
the  	the  	 DT	O
strand  	strand  	 JJ	B-NP
transfer  	transfer  	 NN	I-NP
step  	step  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
HIV  	HIV  	 NNP	B-NP
proviral  	proviral  	 JJ	O
DNA  	DNA  	 NN	O
integration  	integration  	 NN	O
process  	process  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
cellular  	cellular  	 JJ	B-NP
host  	host  	 NN	I-NP
DNA 	DNA 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
selected  	selected  	 JJ	O
dosage  	dosage  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
pivotal  	pivotal  	 JJ	B-NP
phase  	phase  	 NN	I-NP
III  	III  	 NNP	I-NP
studies  	studies  	 NNS	O
( 	( 	 -LRB-	O
subsequently  	subsequently  	 RB	O
approved  	approved  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
regulatory  	regulatory  	 JJ	B-NP
agencies 	agencies 	 NNS	I-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
400mg  	400mg  	 CD	O
bid  	bid  	 NN	O
by  	by  	 IN	O
oral  	oral  	 JJ	B-NP
route  	route  	 NN	I-NP
with  	with  	 IN	O
or  	or  	 CC	O
without  	without  	 IN	O
food 	food 	 NN	O
.  	.  	 .	O
Raltegravir  	Raltegravir  	 NNP	B-NP
has  	has  	 VBZ	O
a  	a  	 DT	O
week  	week  	 NN	B-NP
effect  	effect  	 NN	I-NP
( 	( 	 -LRB-	O
either  	either  	 DT	O
inhibition  	inhibition  	 NN	O
or  	or  	 CC	O
induction 	induction 	 CD	B-NP
)  	)  	 -RRB-	O
on  	on  	 IN	O
the  	the  	 DT	O
hepatic  	hepatic  	 JJ	B-NP
cytochrone  	cytochrone  	 NN	I-NP
P450  	P450  	 CD	I-NP
activity 	activity 	 NN	I-NP
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
not  	not  	 RB	O
need  	need  	 VB	O
of  	of  	 IN	O
dose  	dose  	 NN	O
adjustments  	adjustments  	 NNS	O
in  	in  	 IN	O
renal  	renal  	 JJ	B-NP
insufficiency  	insufficiency  	 NN	I-NP
or  	or  	 CC	O
in  	in  	 IN	O
mild-to-moderate  	mild-to-moderate  	 JJ	B-NP
hepatic  	hepatic  	 JJ	I-NP
impairment 	impairment 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
emerging  	emerging  	 VBG	B-NP
paradigm  	paradigm  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
field  	field  	 NN	O
of  	of  	 IN	O
salvage  	salvage  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
was  	was  	 VBD	O
to  	to  	 TO	O
achieve  	achieve  	 VB	O
a  	a  	 DT	O
viral  	viral  	 JJ	B-NP
load  	load  	 NN	I-NP
below  	below  	 IN	O
limit  	limit  	 NN	O
of  	of  	 IN	O
detection  	detection  	 NN	O
in  	in  	 IN	O
almost  	almost  	 RB	O
all  	all  	 DT	O
patients 	patients 	 NNS	O
.  	.  	 .	O
Pretty  	Pretty  	 RB	O
soon  	soon  	 RB	O
it  	it  	 PRP	O
became  	became  	 VBD	O
apparent  	apparent  	 JJ	O
that  	that  	 IN	O
this  	this  	 DT	O
was  	was  	 VBD	O
feasible  	feasible  	 VBN	O
in  	in  	 IN	O
more  	more  	 JJR	O
than  	than  	 IN	O
70-90 	70-90 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
patients 	patients 	 NNS	O
.  	.  	 .	O
Raltegravir  	Raltegravir  	 NNP	B-NP
proved  	proved  	 VBD	O
to  	to  	 TO	O
be  	be  	 VB	O
pivotal  	pivotal  	 VBN	O
for  	for  	 IN	O
this  	this  	 DT	O
new  	new  	 JJ	O
paradigm 	paradigm 	 NN	O
.  	.  	 .	O
Raltegravir  	Raltegravir  	 JJ	O
vs  	vs  	 JJ	O
placebo  	placebo  	 NN	O
both  	both  	 CC	O
with  	with  	 IN	O
an  	an  	 DT	O
optimized  	optimized  	 JJ	B-NP
background  	background  	 NN	I-NP
therapy  	therapy  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
tested  	tested  	 VBN	O
for  	for  	 IN	O
salvage  	salvage  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
005  	005  	 CD	O
and  	and  	 CC	O
in  	in  	 IN	O
the  	the  	 DT	O
BENCHMRK  	BENCHMRK  	 NNP	B-NP
studies  	studies  	 NNS	I-NP
( 	( 	 -LRB-	O
018  	018  	 CD	O
and  	and  	 CC	O
019 	019 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
all  	all  	 DT	O
three  	three  	 CD	O
studies  	studies  	 NNS	O
proved  	proved  	 VBD	O
to  	to  	 TO	O
be  	be  	 VB	O
superior  	superior  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
placebo  	placebo  	 NN	O
at  	at  	 IN	O
24 	24 	 CD	O
,  	,  	 ,	O
48  	48  	 CD	O
and  	and  	 CC	O
96  	96  	 CD	O
weeks 	weeks 	 NNS	O
.  	.  	 .	O
Tolerance  	Tolerance  	 NNP	O
was  	was  	 VBD	O
remarkably  	remarkably  	 RB	O
good  	good  	 JJ	O
and  	and  	 CC	O
virological  	virological  	 JJ	B-NP
failure  	failure  	 NN	I-NP
was  	was  	 VBD	O
often  	often  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
selection  	selection  	 NN	O
of  	of  	 IN	O
integrase  	integrase  	 JJ	B-NP
gene  	gene  	 NN	I-NP
resistance  	resistance  	 NN	I-NP
mutations  	mutations  	 NNS	I-NP
following  	following  	 VBG	O
the  	the  	 DT	O
Y143C 	Y143C 	 NNP	O
/ 	/ 	 NNP	O
H 	H 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
R 	R 	 NNP	I-NP
,  	,  	 ,	O
Q148H 	Q148H 	 NNP	O
/ 	/ 	 NNP	O
K 	K 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
R  	R  	 NNP	I-NP
o  	o  	 VBD	O
less  	less  	 RBR	O
frequently  	frequently  	 RB	O
the  	the  	 DT	O
NI55H  	NI55H  	 CD	O
paths 	paths 	 NNS	O
.  	.  	 .	O
Finally 	Finally 	 RB	O
,  	,  	 ,	O
in  	in  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
SWITCHMRK  	SWITCHMRK  	 FW	B-NP
studies  	studies  	 FW	I-NP
non-inferiority  	non-inferiority  	 FW	I-NP
vs  	vs  	 FW	O
Lopinavir 	Lopinavir 	 FW	B-NP
/ 	/ 	 FW	I-NP
r  	r  	 FW	I-NP
could  	could  	 MD	O
not  	not  	 RB	O
be  	be  	 VB	O
demonstrated  	demonstrated  	 VBN	O
in  	in  	 IN	O
virogically  	virogically  	 JJ	B-NP
suppressed  	suppressed  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
an  	an  	 DT	O
stable  	stable  	 JJ	O
cART  	cART  	 FW	O
containing  	containing  	 FW	B-NP
Lopinavir 	Lopinavir 	 FW	I-NP
/ 	/ 	 FW	I-NP
r 	r 	 FW	I-NP
.  	.  	 .	O
Most  	Most  	 RBS	O
likely  	likely  	 JJ	O
explanation  	explanation  	 NN	O
was  	was  	 VBD	O
the  	the  	 DT	O
presence  	presence  	 NN	O
of  	of  	 IN	O
archived  	archived  	 JJ	B-NP
resistance  	resistance  	 NN	I-NP
mutationts  	mutationts  	 NN	I-NP
to  	to  	 TO	O
background  	background  	 NN	B-NP
therapy  	therapy  	 NN	I-NP
leading  	leading  	 VBG	O
to  	to  	 TO	O
a  	a  	 DT	O
functional  	functional  	 JJ	B-NP
monotherapy  	monotherapy  	 NN	I-NP
with  	with  	 IN	O
raltegravir 	raltegravir 	 NN	B-NP
.  	.  	 .	O
